Showing results (1-10 of 53) with videos related to
Sort By:
Pageof 6
Trends in Cancer|September 10, 2022
Gut microbiota - a double-edged sword in cancer immunotherapyMiles C Andrews, Ajithkumar VasanthakumarJournal for Immunotherapy of Cancer|February 28, 2017
Immunotherapy resistance: the answers lie ahead - not in front - of usMiles C Andrews, Jennifer A WargoBritish Journal of Cancer|May 20, 2017
Hallmarks of response to immune checkpoint blockadeAlexandria P Cogdill, Miles C Andrews, Jennifer A WargoFuture Oncology (London, England)|July 24, 2014
Evolving role of tumor antigens for future melanoma therapiesMiles C Andrews, Katherine Woods, Jonathan Cebon, et al.The Australasian Journal of Dermatology|May 13, 2016
Late presentation of generalised bullous pemphigoid-like reaction in a patient treated with pembrolizumab for metastatic melanomaSagun Parakh, Rebecca Nguyen, Jacinta M Opie, et al.Frontiers in Immunology|May 22, 2018
Concepts Collide: Genomic, Immune, and Microbial Influences on the Tumor Microenvironment and Response to Cancer TherapyMiles C Andrews, Alexandre Reuben, Vancheswaran Gopalakrishnan, et al.Frontiers in Oncology|January 8, 2015
Effects of epithelial to mesenchymal transition on T cell targeting of melanoma cellsKatherine Woods, Anupama Pasam, Aparna Jayachandran, et al.Immunology and Cell Biology|February 3, 2018
The good, the (not so) bad and the ugly of immune homeostasis in melanomaJessica da Gama Duarte, Katherine Woods, Miles C Andrews, et al.Expert Review of Clinical Immunology|June 19, 2014
Immune consequences of kinase inhibitors in development, undergoing clinical trials and in current use in melanoma treatmentLaura J Vella, Miles C Andrews, Andreas Behren, et al.Cancer Reports (Hoboken, N.J.)|July 29, 2020
A pilot study of intrahepatic yttrium-90 microsphere radioembolization in combination with intravenous cisplatin for uveal melanoma liver-only metastasesSurein Arulananda, Sagun Parakh, Jodie Palmer, et al.Pageof 6